{
    "id": "7dd755fd-d4fe-431a-97a2-1ded5cf1a24b",
    "indications": "releuko leukocyte growth factor indicated : decrease incidence infection‚ manifested febrile neutropenia‚ patients nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated significant incidence severe neutropenia fever . ( 1.1 ) reduce time neutrophil recovery duration fever , following induction consolidation chemotherapy treatment patients acute myeloid leukemia ( aml ) . ( 1.2 ) reduce duration neutropenia neutropenia-related sequelae‚ e.g.‚ febrile neutropenia , patients nonmyeloid malignancies undergoing myeloablative chemotherapy followed bone marrow transplantation ( bmt ) . ( 1.3 ) mobilize autologous hematopoietic progenitor cells peripheral blood collection leukapheresis ( 1.4 ) reduce incidence duration sequelae severe neutropenia ( e.g . , fever‚ infections‚ oropharyngeal ulcers ) symptomatic patients congenital neutropenia‚ cyclic neutropenia‚ idiopathic neutropenia . ( 1.5 ) increase survival patients acutely exposed myelosuppressive doses radiation ( hematopoietic syndrome acute radiation syndrome ) ( 1.6 )",
    "contraindications": "patients cancer receiving myelosuppressive chemotherapy induction and/or consolidation chemotherapy aml . recommended starting dose 5 mcg/kg/day subcutaneous injection , short intravenous infusion ( 15 30 minutes ) , continuous intravenous infusion . full prescribing information recommended adjustments timing ( 2.1 ) patients cancer undergoing bone marrow transplantation 10 mcg/kg/day given intravenous infusion longer 24 hours . full prescribing information recommended adjustments timing . ( 2.2 ) patients undergoing autologous peripheral blood progenitor cell collection therapy 10 mcg/kg/day subcutaneous injection ( 2.3 ) administer least 4 days first leukapheresis procedure continue last leukapheresis ( 2.3 ) patients congenital neutropenia recommended starting dose 6 mcg/kg subcutaneous injection twice daily ( 2.4 ) patients cyclic idiopathic neutropenia recommended starting dose 5 mcg/kg subcutaneous injection daily ( 2.4 ) patients acutely exposed myelosuppressive doses radiation 10 mcg/kg/day subcutaneous injection ( 2.5 ) direct less 0.3 ml ( 180 mcg ) using releuko prefilled syringe recommended due potential dosing errors . ( 2.6 )",
    "warningsAndPrecautions": "releuko ( filgrastim-ayow ) injection clear , colorless , preservative-free solution supplied : vials single-dose vials containing 300 mcg/ml filgrastim-ayow . dispensing packs 10 vials ( ndc 70121-1569-7 ) . single-dose vials containing 480 mcg/1.6 ml ( 300 mcg/ml ) filgrastim-ayow . dispensing packs 10 vials ( ndc 70121-1571-7 ) . prefilled syringes single-dose , prefilled syringe 27 gauge , 1/2 inch needle ultrasafe plustm needle guard , containing 300 mcg/0.5 ml filgrastim-ayow . carton one single-dose prefilled syringe ( ndc 70121-1568-1 ) pack 10 prefilled syringes ( ndc 70121-1568-7 ) . single-dose , prefilled syringe 27 gauge , 1/2 inch needle ultrasafe plustm needle guard , containing 480 mcg/0.8 ml filgrastim-ayow . carton one single-dose prefilled syringe ( ndc 70121-1570-1 ) pack 10 prefilled syringes ( ndc 70121-1570-7 ) . store releuko refrigerated 2°c 8°c ( 36°f 46°f ) original pack protect light . leave releuko direct sunlight . freeze releuko . avoid shaking . transport via pneumatic tube studied .",
    "adverseReactions": "releuko contraindicated patients history serious allergic human granulocyte colony-stimulating factors filgrastim products pegfilgrastim products [ ( 5.3 ) ] .",
    "ingredients": [
        {
            "name": "FILGRASTIM",
            "code": "PVI5M0M1GW"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "Amneal Pharmaceuticals LLC",
    "name": "RELEUKO",
    "effectiveTime": "20250424",
    "indications_original": "RELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 )",
    "contraindications_original": "Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML. Recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion. See Full Prescribing Information for recommended dosage adjustments and timing of administration ( 2.1 ) Patients with cancer undergoing bone marrow transplantation 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. See Full Prescribing Information for recommended dosage adjustments and timing of administration. ( 2.2 ) Patients undergoing autologous peripheral blood progenitor cell collection and therapy 10 mcg/kg/day subcutaneous injection ( 2.3 ) Administer for at least 4 days before first leukapheresis procedure and continue until last leukapheresis ( 2.3 ) Patients with congenital neutropenia Recommended starting dose is 6 mcg/kg subcutaneous injection twice daily ( 2.4 ) Patients with cyclic or idiopathic neutropenia Recommended starting dose is 5 mcg/kg subcutaneous injection daily ( 2.4 ) Patients acutely exposed to myelosuppressive doses of radiation 10 mcg/kg/day subcutaneous injection ( 2.5 ) Direct administration of less than 0.3 mL (180 mcg) using RELEUKO prefilled syringe is not recommended due to potential for dosing errors. ( 2.6 )",
    "warningsAndPrecautions_original": "RELEUKO (filgrastim-ayow) injection is a clear, colorless, preservative-free solution supplied as:\n                  \n                     \n                        Vials\n                     \n                  \n                  Single-dose vials containing 300 mcg/mL of filgrastim-ayow. Dispensing packs of 10 vials (NDC 70121-1569-7).\n                  Single-dose vials containing 480 mcg/1.6 mL (300 mcg/mL) of filgrastim-ayow. Dispensing packs of 10 vials (NDC 70121-1571-7).\n                  \n                     \n                        Prefilled Syringes\n                     \n                  \n                  Single-dose, prefilled syringe with 27 gauge, 1/2 inch needle with an UltraSafe PlusTM Needle Guard, containing 300 mcg/0.5 mL of filgrastim-ayow.\n                  \n                     Carton of one single-dose prefilled syringe (NDC 70121-1568-1) \n                     Pack of 10 prefilled syringes (NDC 70121-1568-7).\n    \n                  \n                  Single-dose, prefilled syringe with 27 gauge, 1/2 inch needle with an UltraSafe PlusTM Needle Guard, containing 480 mcg/0.8 mL of filgrastim-ayow.\n                  \n                     Carton of one single-dose prefilled syringe (NDC 70121-1570-1)\n                     Pack of 10 prefilled syringes (NDC 70121-1570-7).\n                  \n                  Store RELEUKO refrigerated at 2°C to 8°C (36°F to 46°F) in the original pack to protect from light. Do not leave RELEUKO in direct sunlight. DO NOT freeze RELEUKO. Avoid shaking. Transport via a pneumatic tube has not been studied.",
    "adverseReactions_original": "RELEUKO is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products [see Warnings and Precautions (5.3)]."
}